89 followers
Suggesting insufficient efficacy at this dosage schedule :( pubmed.ncbi.nlm.nih.gov/40651101/
Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome
Overview of attention for article published in Leukemia Research, June 2025